Table 1 Patients’ characteristics of the whole collective
From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts
Characteristics | All n = 530 | IT collective n = 347* | IT n = 347* | \(\varvec{\chi}\)2 test♣ | |
|---|---|---|---|---|---|
Primary resistant n = 144 (41.5%) | DC (CR, PR, SD) n = 203 (58.5%) | ||||
Age distribution | 0.383 | ||||
 Median |  | 68 (54.0–74.0) |  |  | |
 < 60 | 197 (37.2%) | 108 (31.1%) | 39 (27.1%) | 69 (34%) | |
 60–75 | 180 (34%) | 127 (36.6%) | 55 (38.2%) | 72 (35.5%) | |
 > 75 | 153 (28.8%) | 112 (32.3%) | 50 (34.7%) | 62 (30.5%) | |
Gender | 0.079 | ||||
 Male | 301 (56.8%) | 207 (59.7%) | 78 (54.2%) | 129 (63.5%) | |
 Female | 229 (43.2%) | 140 (40.3%) | 66 (45.8%) | 74 (36.5%) | |
Tumour localization♦ | 0.007 | ||||
 Head and neck | 85 (20.6%) | 59 (21.5%) | 16 (15.1%) | 43 (25.4%) | |
Trunk | 144 (34.9%) | 81 (29.5%) | 24 (22.6%) | 57 (33.7%) | |
Extremity | 166 (40.2%) | 118 (42.9%) | 57 (53.8%) | 61 (36.1%) | |
Other | 18 (4.3%) | 17 (6.1%) | 9 (8.5%) | 8 (4.8%) | |
Histological subtype♦ | 0.013 | ||||
 SSM | 134 (35.6%) | 80 (31.1%) | 33 (34%) | 47 (29.4%) | |
 NM | 118 (31.4%) | 80 (31.1%) | 22 (22.7%) | 58 (36.3%) | |
 LMM | 17 (4.5%) | 14 (5.4%) | 1 (1%) | 13 (8.1%) | |
 ALM | 37 (9.8%) | 32 (12.5%) | 16 (16.5%) | 16 (10%) | |
 Mucosal | 18 (4.8%) | 17 (6.6%) | 9 (9.3%) | 8 (5.0%) | |
 Other | 52 (13.9%) | 34 (13.3%) | 16 (16.5%) | 18 (11.2%) | |
Stage at initial diagnosis♦ | 0.130 | ||||
 I | 89 19.7%) | 52 (17.4%) | 21 (17.5%) | 31 (17.4%) | |
 II | 129 (28.5%) | 91 (30.5%) | 29 (24.3%) | 62 (34.8%) | |
 III | 159 (35.2%) | 105 (35.3%) | 44 (36.7%) | 61 (34.3%) | |
 IV | 75 (16.6%) | 50 (16.8%) | 26 (21.7%) | 24 (13.5%) | |
Number of organs with metastases | 0.03 | ||||
 1–3 | 462 (87.2%) | 309 (89%) | 122 (84.7%) | 187 (92.1%) | |
 > 3 | 68 (12.8%) | 38 (11%) | 22 (15.3%) | 16 (7.9%) | |
Brain metastases | 0.901 | ||||
 No brain metastases | 404 (76.2%) | 283 (81.6%) | 117 (81.2%) | 166 (81.8) | |
 Brain metastases | 126 (23.8%) | 64 (18.4%) | 27 (18.8%) | 37 (18.2%) | |
Liver metastases | 0.065 | ||||
 No liver metastases | 338 (63.8%) | 222 (64%) | 84 (58.3%) | 138 (68%) | |
 Liver metastases | 192 (36.2%) | 125 (36%) | 60 (41.7%) | 65 (32%) | |
BRAF mutation♦ | 0.529 | ||||
 BRAF mutation | 216 (59.7%) | 96 (44.9%) | 35 (42.2%) | 61 (46.6%) | |
 BRAF wild type | 146 (40.3%) | 118 (55.1%) | 48 (57.8%) | 70 (53.4%) | |
LDH level♦ | 0.016 | ||||
 Normal | 279 (62.1%) | 200 (66.2%) | 73 (58.4%) | 127 (71.8%) | |
 Elevated | 170 (37.9%) | 102 (33.8%) | 52 (41.6%) | 50 (28.2%) | |
S100 level♦ | 0.000 | ||||
 Normal | 230 (51.5%) | 168 (54.7%) | 51 (40.8%) | 117 (64.3%) | |
 Elevated | 217 (48.5%) | 139 (45.3%) | 74 (59.2%) | 65 (35.7%) | |